title: Predicting survival and post-operative complications with Tc-GSA liver scintigraphy in hepatocellular carcinoma.
abstract: OBJECTIVE
  Technetium-99m galactosyl human serum albumin is a novel liver scintigraphic agent. The aim of the present study was to examine whether liver scintigraphy with this agent could predict changes in hepatic function affecting survival in patients with inoperable hepatocellular carcinoma and liver cirrhosis. We also investigated whether the risk of major complications after hepatectomy for hepatocellular carcinoma could be assessed.
  
  
  METHODS
  Liver scintigraphy was performed in 42 patients with inoperable hepatocellular carcinoma and cirrhosis and 40 patients undergoing hepatectomy. The ratio of liver to heart plus liver radioactivity 15 min after injection (LHL15) was calculated.
  
  
  RESULTS
  The 1-year survival rates were higher in patients with higher LHL15: 100%, LHL15 > or = 0.91; 77.8%, 0.81 < or = LHL15 < or = 0.90; and 28.6%, LHL15 < or = 0.80. On multifactorial analysis, LHL15 significantly predicted the 1-year mortality rate in the 42 patients (p<0.001). Pre-operative LHL15 was significantly lower in 9 patients with major post-operative complications (0.88+/-0.02) than in 31 patients with uneventful courses or minor post-operative complications (0.93+/-0.01, p<0.001).
  
  
  CONCLUSIONS
  Our results suggest that technetium-99m galactosyl human serum albumin liver scintigraphy is effective for predicting short-term survival in patients with inoperable HCC and cirrhosis and for assessing the risk of major complications after hepatectomy.
authors.affiliation: Department of Surgery, Showa University Fujigaoka Hospital, Yokohama, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Takeuchi
authors.forename: H
authors.initials: H
authors.lastname: Nakano
authors.forename: Y K
authors.initials: YK
authors.lastname: Kim
authors.forename: K
authors.initials: K
authors.lastname: Kumada
authors.forename: H
authors.initials: H
authors.lastname: Nagasaki
authors.forename: J
authors.initials: J
authors.lastname: Sasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Sanada
authors.forename: Y
authors.initials: Y
authors.lastname: Baek
authors.forename: S
authors.initials: S
authors.lastname: Hasebe
authors.forename: T
authors.initials: T
authors.lastname: Midorikawa
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshizawa
authors.forename: M
authors.initials: M
authors.lastname: Yamaguchi
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000401:mortality / Q000601:surgery*; D005260:Female; D006498:Hepatectomy; D006801:Humans; D008099:Liver / Q000000981:diagnostic imaging; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000000981:diagnostic imaging* / Q000401:mortality; D011379:Prognosis; D011877:Radionuclide Imaging; D015996:Survival Rate; D013668:Technetium Tc 99m Aggregated Albumin
chemical_list: D013668:Technetium Tc 99m Aggregated Albumin